Positive Reimbursement Coverage Continues for Aerocrine's Asthma Test
Published: Oct 09, 2012
SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Aerocrine AB (STO:AERO-B) announces that Medica Health Plans of Minnesota, a Blue Cross Blue Shield company, has updated its reimbursement policy for FeNO testing and provides positive coverage effective September 19, 2012. On September 19, 2012, Medica Health Plans published a positive coverage policy regarding Fractional exhaled Nitric Oxide (FeNO) testing. Specifically, FeNO testing is covered for the treatment of asthma when it is used in the diagnosis of allergic airway inflammation or when used in determining likelihood of steroid responsiveness in individuals with chronic symptoms suggestive of allergic airway inflammation.